John Cox (Photo: Repligen)

The time is now: John Cox as­sumes CEO post at Flag­ship-backed Torque, steer­ing cell ther­a­py to clin­i­cal tri­als

A stealthy Torque Ther­a­peu­tics is in the midst of rais­ing a Se­ries B round to bankroll an up­com­ing slate of clin­i­cal stud­ies for its can­cer cell ther­a­py plat­form — and it will all be over­seen by a new CEO.

John Cox, ex­ec­u­tive chair­man since Jan­u­ary, is tak­ing over from Bart Hen­der­son as the for­mer chief pur­sues some oth­er work with Flag­ship Pi­o­neer­ing.

The ap­point­ment marks the first full-time gig for Cox since he flipped Bio­gen’s he­mo­phil­ia-fo­cused spin­out Biover­a­tiv to Sanofi for $11.6 bil­lion, earn­ing a pay­out worth more than $85 mil­lion in the process. The lit­tle taste he had of cell ther­a­py there, al­beit for a dis­tinct­ly dif­fer­ent ap­pli­ca­tion, helped con­vince him that it’s a modal­i­ty for the fu­ture. He en­vi­sions Torque be­com­ing the de­fin­i­tive im­muno-on­col­o­gy cell ther­a­py com­pa­ny, and the time is now to jump in.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.